Hypogonadotropic Hypogonadism Clinical Trial
Official title:
Baselines in Reproductive Disorders
The purpose of the study is to explore the way in which gonadotropins (pituitary hormones)
are released into the body. The knowledge acquired in this study will be used for the
diagnosis and treatment of reproductive endocrine disorders.
We seek to investigate the baseline characteristics of the GnRH-induced gonadotropin
pulsations of patients with the following diagnoses:
- Hypothalamic Amenorrhea (HA)
- Idiopathic hypogonadotropic hypogonadism (IHH)
- Polycystic ovarian disease (PCOD)
- Acquired hypogonadotropic hypogonadism (AHH)
- Premature Ovarian Failure (POF)
**WE ARE CURRENTLY RECRUITING ONLY SUBJECTS WITH A DIAGNOSIS OF IHH.**
This has been an extremely productive and pivotal protocol in the studies of female
reproductive physiology and pathophysiology and continues to be critical for defining the
neuroendocrine abnormalities in patients with reproductive disorders. In some cases, it is
also helpful in the planning of subsequent therapy if so desired.
It is important to note that minors have been included in this protocol, as many patients
are extremely anxious to know more about their neuroendocrine disorder. With minors who
would like to know if their disorder is correctable, this protocol may be followed up with
administration of pulsatile gonadotropin-releasing hormone (GnRH).
Normal reproductive cycles in women require the integrated function of the hypothalamus,
pituitary and ovaries. The hypothalamic component of the reproductive system can be assessed
directly in lower animal species by measurement of gonadotropin releasing hormone (GnRH)
directly from pituitary portal blood and recording of multiunit activity from the median
eminence of the hypothalamus, providing direct information about the physiology of GnRH
secretion and the activity of the GnRH pulse generator. However, these techniques are not
feasible in the human. In addition, measurement of GnRH levels in peripheral blood does not
accurately reflect hypothalamic GnRH secretion. Thus, indirect methods must be used to gain
insight into hypothalamic function in the human.
In the human, pulsatile luteinizing hormone (LH) secretion has been used as a mirror of
hypothalamic GnRH secretion, citing comparative data from the rat, sheep, and non-human
primate which indicate that pulses of LH are directly linked to antecedent pulses of GnRH.
LH secretion thus provides an estimate of the underlying frequency of GnRH pulse generator
activity provided that the assay is sufficiently precise, with a low coefficient of
variation, and that blood sampling is frequent enough to accurately reflect the underlying
frequency of episodic GnRH pulsatility. The use of pulsatile secretion of the free alpha
subunit (FAS) of the gonadotropins has recently been proposed as an alternative and improved
marker of GnRH secretion in the human due to a half-life of 15 minutes versus 20 to 40
minutes for LH. Despite the dual control of FAS by GnRH and thyroid releasing hormone (TRH),
our studies have shown that the pulsatile component of FAS secretion is driven solely by
GnRH in euthyroid subjects. Such studies have indicated:
1. the nearly complete concordance of pulses of FAS with those of LH in normal women, and
in GnRH-deficient subjects undergoing GnRH replacement;
2. the absence of pulsatile secretion of FAS in GnRH-deficient subjects; and
3. the abolition of pulsatile FAS secretion in concert with that of LH following
administration of a GnRH antagonist in normal and postmenopausal women.
We have proposed that abnormalities in the pulsatile secretion of GnRH underlie many
reproductive abnormalities and that these may explain the clinical variability, which exists
even within a given diagnostic category. In this protocol, we have sought to define the
specific neuroendocrine profile in patients with amenorrhea or oligomenorrhea. In some
patients, the results of these studies can then correlated with clinical outcomes of
ovulation induction protocols and with genotype information. We have examined the spectrum
of abnormal patterns of LH (and by inference GnRH) secretion in women with secondary
hypogonadotropic hypogonadism. In 73 studies in 50 women, it has been determined that the
most common neurosecretory defect is low frequency/low amplitude followed by normal
frequency/normal amplitude, apulsatile, and low amplitude/normal frequency. Of patients
studied on several occasions, 75% demonstrated at least 2 different patterns of LH secretion
and 33% reverted at least once to a normal pattern of secretion. Study of the baseline
patterns of LH secretion in patients with acquired GnRH deficiency/acquired hypothalamic
hypogonadism (AHH) indicates that this group of patients has either an apulsatile pattern or
a pattern of low amplitude LH pulses in comparison with normal women in the early follicular
phase (matched for ovarian steroid levels). In these patients, the specific LH pattern does
not predict response to pulsatile GnRH used for ovulation induction. FAS is apulsatile in
the majority of patients with primary amenorrhea and absent LH pulses providing further
support for the hypothesis that the pulsatile component of FAS secretion is primarily driven
by GnRH in euthyroid patients despite the dual control of FAS by GnRH and TRH. As in men
with presumed GnRH deficiency, occasional patients with absent LH pulses will have FAS
pulses. These interesting patients are being further evaluated with respect to their pattern
of TSH secretion and the bioactivity of their LH.
;
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01438073 -
Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling
|
Phase 1 | |
Completed |
NCT01403532 -
Sequential Therapy for Hypogonadotropic Hypogonadism
|
Phase 4 | |
Terminated |
NCT05205837 -
A Randomized, Double-blinded, Clinical, Placebo-controlled Trial on the Effects of Therapy With Letrozole and hUman Choriongonadotropin in Male Hypogonadism Induced by Illicit Use of Anabolic Androgenic Steroids- The LUCAS Trial
|
Phase 4 | |
Completed |
NCT02908074 -
A 6 Month Safety Extension Study of MBGS205
|
Phase 2 | |
Completed |
NCT05752591 -
Hypothalamic-pituitary Dysfunction in Diabetes
|
||
Terminated |
NCT03118479 -
Effect of Varying Testosterone Levels on Insulin Sensitivity in Men With Idiopathic Hypogonadotropic Hypogonadism (IHH)
|
Phase 1 | |
Completed |
NCT02730169 -
Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism
|
Phase 2 | |
Completed |
NCT02110368 -
Bioequivalence Study of Test and Reference Testosterone Topical Gel, 1.62% Metered Pump in Testosterone Deficient Adult Male Subjects Under Fasting Conditions
|
Phase 3 | |
Recruiting |
NCT01601171 -
Genetics of Reproductive Disorders (Including Kallmann Syndrome) and Cleft Lip and/or Palate
|
||
Completed |
NCT01623570 -
Clinical Outcomes in WHO Type I Anovulatory Women Using r-hFSH+r-hLH in a 2:1 Ratio or hMG-HP
|
N/A | |
Terminated |
NCT00328926 -
Luveris® (Lutropin Alfa for Injection) in Women With Hypogonadotropic Hypogonadism (Luteinizing Hormone [LH] Less Than [<] 1.2 International Unit Per Liter [IU/L])
|
Phase 4 | |
Completed |
NCT01438034 -
Kisspeptin in the Evaluation of Delayed Puberty
|
Phase 1 | |
Completed |
NCT04456296 -
A Study of the Effect of Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism
|
Phase 4 | |
Recruiting |
NCT00914823 -
Kisspeptin Administration in the Adult
|
Phase 1 | |
Terminated |
NCT01155518 -
Hypogonadism in Young Men With Type 2 Diabetes
|
Phase 2 | |
Completed |
NCT00697814 -
Clomiphene in Males With Prolactinomas and Persistent Hypogonadism
|
Phase 2 | |
Active, not recruiting |
NCT00351416 -
Letrozole Treatment in Normal and GnRH Deficient Women
|
Phase 2/Phase 3 | |
Recruiting |
NCT05971836 -
The Molecular Basis of Inherited Reproductive Disorders
|
||
Recruiting |
NCT02705014 -
Efficacy of Pulsatile GnRH Therapy on Male Patients With Pituitary Stalk Interruption Syndrome
|
N/A | |
Recruiting |
NCT04648969 -
Prolonged Pulsatile Kisspeptin Administration in Hypogonadotropic Hypogonadism
|
Phase 2 |